Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Clinical trial NCT07185997 · RECRUITING

Trial details

NCT number: NCT07185997
Sponsor: ArriVent BioPharma, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small-Cell Lung Cancer Metastatic Non-Small-Cell Lung Cancer Advanced Non-Small-Cell Lung Cancer EGFR P-Loop and Alpha C-Helix Compressing EGFR PACC EGFR Uncommon Mutations

Start date: 2025-12-17
Primary completion: 2029-02-01
Enrollment: 480

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.